Evaluation of inactive Matrix-Gla-Protein (MGP) as a biomarker for incident and recurrent kidney stones

Castiglione, Vincent; Pottel, Hans; Lieske, John C.; Lukas, Pierre; Cavalier, Étienne; Rule, Andrew D.

doi:10.1007/s40620-019-00623-0

Cited by 10 publications

(7 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In a Mendelian randomization study 291 , increased levels of circulating plasma dp-ucMGP were associated with an increased risk of stone disease ( P < 0.05). In a prospective study including first-time kidney stone formers and matched non-stone formers 292 , no association between serum dp-ucMGP and stone incidence or recurrence was observed ( P = 0.66). The reasons for the different outcomes of these studies are difficult to ascertain, and multicentred studies are needed to confirm the validity of the findings.…”

Section: Vitamin Kmentioning

confidence: 92%

Vitamins as regulators of calcium-containing kidney stones — new perspectives on the role of the gut microbiome

Chmiel

Stuivenberg

et al. 2023

Nat Rev Urol

View full text Add to dashboard Cite

Calcium-based kidney stone disease is a highly prevalent and morbid condition, with an often complicated and multifactorial aetiology. An abundance of research on the role of specific vitamins (B 6 , C and D) in stone formation exists, but no consensus has been reached on how these vitamins influence stone disease. As a consequence of emerging research on the role of the gut microbiota in urolithiasis, previous notions on the contribution of these vitamins to urolithiasis are being reconsidered in the field, and investigation into previously overlooked vitamins (A, E and K) was expanded. Understanding how the microbiota influences host vitamin regulation could help to determine the role of vitamins in stone disease.

show abstract

Section: Vitamin Kmentioning

confidence: 92%

Vitamins as regulators of calcium-containing kidney stones — new perspectives on the role of the gut microbiome

Chmiel

Stuivenberg

et al. 2023

Nat Rev Urol

View full text Add to dashboard Cite

show abstract

“…It may be possible for MGP to hinder crystallisation in the kidney, where it is expressed. In vitro, MGP expression was elevated in NRK-52E tubular cells and in rat kidneys upon exposure to calcium oxalate crystals (in vivo) (21). Vascular calcification is a dynamic process involving proteins and molecules rather than a passive, degenerative, incurable illness.…”

Section: Matrix Gla Proteinmentioning

confidence: 99%

Renal caliculi: Types, mechanism, therapeutic approaches encompassing role of GAGS, MGP, Hormones, UPTF1, CAI, Osteopontin

Mamatha M,

Ganga Raju M,

NVL Suvarchala Reddy V

et al. 2024

Int. J. Sci. Res. Arch.

View full text Add to dashboard Cite

Kidney stones are deposits in the renal pelvis, calyces, and ureters and reside in urine. Kidney stones undergo biomineralization pathogenesis via nucleation, aggregation, and growth of caliculi. The greater prevalence of kidney stones in men than in women may be due to the link between sex hormones. Kidney equilibrium is maintained with glycosaminoglycans inhibiting growth and aggregation. Sialylated glycoforms of urinary prothrombin fragment 1 prevent calcium stone development. Crystal adherence to tubules is inhibited by CAI, and osteopontin inhibits calculi formation. Medical treatments involve the use of alpha blocker, potassium citrate, thiazide, NSAIDS, opioids, antiemetics and other drugs used in treatment of kidney stone, Alpha adrenoceptor blockers, calcium channel blockers and corticosteroids help to expel renal stones, chemolytic treatment and it could be necessary to remove stones surgically if they are affecting kidney function with the use of techniques. Use of catheter, ultrasound, using a flexible scope equipped with a laser, HDAC inhibitors and many are recent advances in treatment lithiasis.

show abstract

“…Matrix Gla protein (MGP) was identified in the bone matrix and then in other tissues, including vascular [108]. Although it is suspected to have an inhibitory effect on calcification, the recent study on stone formers does not confirm this hypothesis [24,108].…”

Section: Matrix Gla Proteinmentioning

confidence: 99%

“…Castiglione V. et al [24] Evaluation of inactive Matrix-Gla-Protein (MGP) as a biomarker for incident and recurrent kidney stones.…”

mentioning

confidence: 99%

Current Status of Protein Biomarkers in Urolithiasis—A Review of the Recent Literature

Lasota,

Wasilewska,

Rybi-Szumińska

2023

JCM

View full text Add to dashboard Cite

Urolithiasis is an increasingly common clinical problem worldwide. The formation of stones is a combination of metabolic status, environmental factors, family history and many other aspects. It is important to find new ways to quickly detect and assess urolithiasis because it causes sudden, severe pain and often comes back. One way to do this is by exploring new biomarkers. Current advances in proteomic studies provide a great opportunity for breakthroughs in this field. This study focuses on protein biomarkers and their connection to kidney damage and inflammation during urolithiasis.

show abstract

Evaluation of inactive Matrix-Gla-Protein (MGP) as a biomarker for incident and recurrent kidney stones

Cited by 10 publications

References 26 publications

Vitamins as regulators of calcium-containing kidney stones — new perspectives on the role of the gut microbiome

Vitamins as regulators of calcium-containing kidney stones — new perspectives on the role of the gut microbiome

Renal caliculi: Types, mechanism, therapeutic approaches encompassing role of GAGS, MGP, Hormones, UPTF1, CAI, Osteopontin

Current Status of Protein Biomarkers in Urolithiasis—A Review of the Recent Literature

Contact Info

Product

Resources

About